IFX-1 is a monoclonal antibody that targets the proinflammatory complement component C5a.
Alexander P J Vlaar, PhD, Sanne de Bruin, MD, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. September 28, 2020. DOI: https://doi.org/10.1016/S2665-9913(20)30341-6
Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. April 07, 2020. DOI: 10.1101/2020.03.29.20041962., , et al.